Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.

被引：3
|
作者：
Poorvu, Philip Daniel
Gelber, Shari I.
Rosenberg, Shoshana M.
Ruddy, Kathryn Jean
Tamimi, Rulla
Peppercorn, Jeffrey M.
Schapira, Lidia
Borges, Virginia F.
Come, Steven E.
Collins, Laura C.
Warner, Ellen
Partridge, Ann H.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Ctr, Palo Alto, CA USA
[6] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Harvard Med Sch, Boston, MA USA
[9] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
533
引用
收藏
页数：2
相关论文
共 50 条
  • [31] BUDGET IMPACT ANALYSIS OF THE ONCOTYPE DX BREAST CANCER RECURRENCE SCORE TEST TO GUIDE CHEMOTHERAPY USE IN ER+/HER2-NODE-NEGATIVE EARLY INVASIVE BREAST CANCER
    Berdunov, V
    Millen, S.
    Paramore, A.
    Reynia, S.
    Fryer, N.
    Griffin, J.
    Floros, L.
    Georges, N.
    VALUE IN HEALTH, 2021, 24 : S26 - S26
  • [32] Oncotype DX Breast Recurrence Score(R): A Review of its Use in Early-Stage Breast Cancer
    Syed, Yahiya Y.
    MOLECULAR DIAGNOSIS & THERAPY, 2020, 24 (05) : 621 - 632
  • [33] Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.
    Munoz-Arcos, Laura Sofia
    Nicolo, Eleonora
    Newman, Lisa A.
    Cigler, Tessa
    Andreopoulou, Eleni
    Moore, Anne
    Donahue, Jeannine
    Cristofanilli, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2-breast cancer
    Coelho, Joao Queiros
    Lau, Beatriz
    Pichel, Rita
    Guerra, Laura
    Miranda, Hugo
    Romao, Raquel
    Sousa, Maria Joao
    Goncalves, Fernando
    Simoes, Joana
    Azevedo, Sergio Xavier
    Araujo, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [36] Decentral gene expression analysis for ER+/Her2-breast cancer: results of a proficiency testing program for the EndoPredict assay
    Denkert, Carsten
    Kronenwett, Ralf
    Schlake, Werner
    Bohmann, Kerstin
    Penzel, Roland
    Weber, Karsten E.
    Hoefler, Heinz
    Lehmann, Ulrich
    Schirmacher, Peter
    Specht, Katja
    Rudas, Margaretha
    Kreipe, Hans-Heinrich
    Schraml, Peter
    Schlake, Gudrun
    Bago-Horvath, Zsuzsanna
    Tiecke, Frank
    Varga, Zsuzsanna
    Moch, Holger
    Schmidt, Marcus
    Prinzler, Judith
    Kerjaschki, Dontscho
    Sinn, Bruno Valentin
    Mueller, Berit Maria
    Filipits, Martin
    Petry, Christoph
    Dietel, Manfred
    VIRCHOWS ARCHIV, 2012, 460 (03) : 251 - 259
  • [37] Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
    Luca Licata
    Giulia Viale
    Mario Giuliano
    Giuseppe Curigliano
    Mariana Chavez-MacGregor
    Julia Foldi
    Oluchi Oke
    Joseph Collins
    Lucia Del Mastro
    Fabio Puglisi
    Filippo Montemurro
    Claudio Vernieri
    Lorenzo Gerratana
    Sara Giordano
    Alessia Rognone
    Lorenzo Sica
    Oreste Davide Gentilini
    Stefano Cascinu
    Lajos Pusztai
    Antonio Giordano
    Carmen Criscitiello
    Giampaolo Bianchini
    npj Breast Cancer, 9
  • [38] Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
    Licata, Luca
    Viale, Giulia
    Giuliano, Mario
    Curigliano, Giuseppe
    Chavez-MacGregor, Mariana
    Foldi, Julia
    Oke, Oluchi
    Collins, Joseph
    Del Mastro, Lucia
    Puglisi, Fabio
    Montemurro, Filippo
    Vernieri, Claudio
    Gerratana, Lorenzo
    Giordano, Sara
    Rognone, Alessia
    Sica, Lorenzo
    Gentilini, Oreste Davide
    Cascinu, Stefano
    Pusztai, Lajos
    Giordano, Antonio
    Criscitiello, Carmen
    Bianchini, Giampaolo
    NPJ BREAST CANCER, 2023, 9 (01)
  • [39] Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad, Juhi
    Jacobson, Allyson F.
    Estabrook, Alison
    Smith, Sharon Rosenbaum
    Boolbol, Susan K.
    Feldman, Sheldon M.
    Osborne, Michael P.
    Boachie-Adjei, Kwadwo
    Twardzik, Wendy
    Tartter, Paul I.
    AMERICAN JOURNAL OF SURGERY, 2008, 196 (04): : 527 - 529
  • [40] Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2-breast cancer?
    Groheux, David
    Hindie, Elif
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1571 - 1573
12345